In March 2018, BioViva announced an exclusive collaboration with Integrated Health Systems Ltd (IHS) to analyse biomarker data on patients who have received access to consensual gene and cell therapies. Today’s investors are wary of drug development companies which typically take decades to progress and provide lack of evidence regarding human performance. Due to this time lag, it is difficult for small companies to stay in business while waiting for funding. To solve this problem of efficient translation of medicine, IHS will help patients in need get access to treatments, whereas BioViva has built a platform to get accurate patient data and help investors know where to put their money.
Bioviva has developed a platform for advanced gene and cell therapeutics. It is connecting researchers with medical doctors to collect data, and provide lack of evidence if some of the most promising therapies in regenerative medicine are working in patients. To this end, BioViva is committed to the following:
BioViva has spent years finding the most meaningful way to most affordably help patients get access to therapeutics and track the data on those patients. To ensure we understand what is happening after treatment. BioViva CEO Liz Parrish states, “The ability to partake in a treatment is a human’s right, to be able to do it as safely as possible is a medical doctor’s job, and proving whether the therapy works is BioViva’s work”.
“This platform will expedite drug funding and therefore drug development by years.” says Liz Parrish. “ Investors need to know what drugs are working before funding lengthy trials. We are not a one treatment company. Rather, we want to be one platform for all the promising biotech therapeutic companies.”
In this respect, BioViva is a platform company with the principles as described in this release.
BioViva USA, Inc. – Delivering on patient access with analysis.
BioViva is a platform to expedite the development of drugs and treatments that affect human healthspan. To achieve this goal, BioViva has developed a comprehensive set of aging biomarkers that includes molecular, physiological, anatomical, clinical, and qualitative markers. BioViva also collaborates with clinicians, biomedical scientists and statisticians to develop innovative protocols for adaptive clinical trials for gene and cells therapies. Finally, BioViva has built a bioinformatics pipeline to analyse the data generated from the biomarkers of aging in human trials, where they validate the treatments that are effective for treating the aging process.
BioViva has recently partnered with the patient-paid-for clinical trial company Integrated Health Systems (IHS). IHS connects doctors with patients who want to take part in paid-for clinical trials. During our collaboration with IHS they will utilise our adaptive clinical trial protocols to conduct gene and cell therapy trials. All patients will undergo pre – and post-testing using BioViva’s comprehensive biomarkers of aging platform. Treatment efficacy and patient well being will be assessed using our bioinformatics pipeline.
The goal of BioViva is to accelerate the development of products that will effectively and cost-efficiently treat biological aging. Our platform is designed to provide expedited and reliable feedback to our clinical and manufacturing partners, to help them rapidly iterate their products and services to help patients improve the quality and quantity of life.
Success for BioViva entails finding therapies that work quantitatively by reversing or slowing biological aging in humans as measured by DNA methylation, as well as by metabolic, physiological, anatomical, and clinical markers. In addition, we will qualitatively improve patient well-being by helping them achieve an optimal healthy life.
BioViva is a platform for anti-aging biotech development. BioViva is to biotech, what meta-analysis is to medical research. BioViva’s platform is designed to accommodate all forms of research and development that target the aging process in humans. We work with biotech companies and biologic manufacturers, and help them conduct accelerated adaptive clinical trials to ascertain the efficacy of their products in treating the aging process.
According to FDA drug approvals between 2004 and 2014, there is a 15 percent chance of going from Phase 1 through to FDA approvals for biologics, and a 7 percent chance of success for small molecules. This high rate of failure highlights the problems with preliminary drug testing platforms. BioViva is a cost-effective solution for biotech companies to rapidly test their drugs in humans, in order to determine where to embark on the expensive and time-consuming FDA or EMA approval process.
The biggest challenge in evaluating the efficacy of anti-aging treatments are biomarkers of aging. Currently, the best biomarkers of aging are loosely associated with biological aging. Especially in people aged over 50.
This is clearly a major problem as we cannot wait for 10 years to test every treatment. Therefore at BioViva we have designed a comprehensive biomarker of aging platform that should be able to ascertain anti-aging treatment efficacy within a couple of years.
In summary, we want to help humans live long and healthy lives. And we have built a platform to assess anyone’s products that can help us achieve that goal.